| Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma Y Yang, AL Shaffer III, NCT Emre, M Ceribelli, M Zhang, G Wright, W Xiao, ... Cancer cell 21 (6), 723-737, 2012 | 449 | 2012 |
| NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis AK Pandey, Y Yang, Z Jiang, SM Fortune, F Coulombe, MA Behr, ... PLoS Pathog 5 (7), e1000500, 2009 | 273 | 2009 |
| NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2 Y Yang, C Yin, A Pandey, D Abbott, C Sassetti, MA Kelliher Journal of Biological Chemistry 282 (50), 36223-36229, 2007 | 237 | 2007 |
| Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide F Coulombe, M Divangahi, F Veyrier, L de Léséleuc, JL Gleason, Y Yang, ... Journal of Experimental Medicine 206 (8), 1709-1716, 2009 | 224 | 2009 |
| Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains DW Abbott, Y Yang, JE Hutti, S Madhavarapu, MA Kelliher, LC Cantley Molecular and cellular biology 27 (17), 6012-6025, 2007 | 198 | 2007 |
| Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors M Ceribelli, PN Kelly, AL Shaffer, GW Wright, W Xiao, Y Yang, LAM Griner, ... Proceedings of the National Academy of Sciences 111 (31), 11365-11370, 2014 | 151 | 2014 |
| Pathogenetic importance and therapeutic implications of NF‐κB in lymphoid malignancies KH Lim, Y Yang, LM Staudt Immunological reviews 246 (1), 359-378, 2012 | 151 | 2012 |
| A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-κB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage Y Yang, F Xia, N Hermance, A Mabb, S Simonson, S Morrissey, P Gandhi, ... Molecular and cellular biology 31 (14), 2774-2786, 2011 | 125 | 2011 |
| Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms Y Yang, R Schmitz, J Mitala, A Whiting, W Xiao, M Ceribelli, GW Wright, ... Cancer discovery 4 (4), 480-493, 2014 | 124 | 2014 |
| Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy PN Kelly, DL Romero, Y Yang, AL Shaffer III, D Chaudhary, S Robinson, ... Journal of Experimental Medicine 212 (13), 2189-2201, 2015 | 113 | 2015 |
| Targeting non-proteolytic protein ubiquitination for the treatment of diffuse large B cell lymphoma Y Yang, P Kelly, AL Shaffer III, R Schmitz, HM Yoo, X Liu, D Webster, ... Cancer cell 29 (4), 494-507, 2016 | 74 | 2016 |
| Targeting the HTLV-I-regulated BATF3/IRF4 transcriptional network in adult T cell leukemia/lymphoma M Nakagawa, AL Shaffer III, M Ceribelli, M Zhang, G Wright, W Xiao, ... Cancer Cell 34 (2), 286-297. e10, 2018 | 39 | 2018 |
| Activation of NOD receptors by Neisseria gonorrhoeae modulates the innate immune response N Mavrogiorgos, S Mekasha, Y Yang, MA Kelliher, RR Ingalls Innate immunity 20 (4), 377-389, 2014 | 37 | 2014 |
| Disruption of thrombocyte and T lymphocyte development by a mutation in ARPC1B R Somech, A Lev, YN Lee, AJ Simon, O Barel, G Schiby, C Avivi, ... The Journal of Immunology 199 (12), 4036-4045, 2017 | 34 | 2017 |
| Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma SK Barta, J Zain, AW MacFarlane IV, SM Smith, J Ruan, HC Fung, CR Tan, ... Clinical Lymphoma Myeloma and Leukemia 19 (6), 356-364. e3, 2019 | 33 | 2019 |
| A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice KM Draheim, N Hermance, Y Yang, E Arous, J Calvo, MA Kelliher Oncogene 30 (10), 1252-1260, 2011 | 29 | 2011 |
| A novel model of controlling PD-L1 expression in ALK+ anaplastic large cell lymphoma revealed by CRISPR screening JP Zhang, Z Song, HB Wang, L Lang, YZ Yang, W Xiao, DE Webster, ... Blood 134 (2), 171-185, 2019 | 20 | 2019 |
| Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma T Pazina, AM James, KB Colby, Y Yang, A Gale, A Jhatakia, AY Kearney, ... Cancer immunology research, 2019 | 8 | 2019 |
| A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-κB and p38 MAP kinase/MAPKAP-2 responses to DNA damage Y Yang, F Xia, N Hermance, A Mabb, S Simonson, S Morrissey, P Gandhi, ... Molecular and Cellular Biology, 2011 | 6 | 2011 |
| A20 and RBX1 regulate brentuximab vedotin sensitivity in Hodgkin lymphoma models W Wei, Y Lin, Z Song, W Xiao, L Chen, J Yin, Y Zhou, SK Barta, M Petrus, ... Clinical Cancer Research 26 (15), 4093-4106, 2020 | 4 | 2020 |
